A. Lowe

发表

A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy

G. Weiss, J. Stephenson, Julie C Martin, 2012, Investigational New Drugs.

Phase I I S tudy o f R ituximab i n C ombination W ith C HOP Chemotherapy i n P atients W ith P reviously U ntreated, Aggressive N on-Hodgkin's L ymphoma

M. Czuczman, P. Gilman, A. Grillo‐López, 2001 .

Phase II Study of Rituximab in Combinat ion With CHOP Chemotherapy in Pat ients With Prev ious ly Untreated , Aggress ive Non-Hodgkin ’ s Lymphoma

J. Vose, M. Czuczman, R. Fisher, 2000 .

Dual thrombolytic therapy with mutant pro-urokinase and small bolus alteplase for ischemic stroke (DUMAS): study protocol for a multicenter randomized controlled phase II trial

Hester F. Lingsma, D. Nieboer, H. D. den Hertog, 2022, Trials.

Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study.

J. Wittes, R. Giugliani, J. E. Wraith, 2006, The Journal of pediatrics.

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Ronald Levy, John P Leonard, Patrick B Johnston, 2010, Blood.

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.

R. Figlin, J. Brugarolas, T. Choueiri, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.

J. Vose, M. Czuczman, R. Fisher, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.

Jeffrey A Jones, M. Grever, J. Byrd, 2012 .

Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis.

H. Deeg, J. Wood, Z. Estrov, 2009 .

Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (SLL/CLL)

J. Vose, A. LaCasce, J. Friedberg, 2008 .

Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1{alpha}.

R. Herbst, R. Kurzrock, G. Weiss, 2010 .

Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM).

B. Barlogie, S. Jagannath, S. Lonial, 2006 .